Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Perfluorohexyloctane (Miebo) is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
• The information is derived from a systematic review and meta-analysis, which analyzed six randomized controlled trials (RCTs).
• Compared to control interventions, perfluorohexyloctane showed significant improvements in eye dryness score, ocular surface disease index, lipid layer thickness, and total corneal fluorescein staining.
• Fewer ocular treatment-emergent adverse events were reported with perfluorohexyloctane compared to controls; however, it was slightly less effective in improving tear film break-up time.
• High patient satisfaction was noted with perfluorohexyloctane tear substitutes according to the systematic review.
• No specific population types or subgroup considerations were provided; the study appears to have adopted a general population of DED patients.